Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 11-19

  Stauffer, Virginia ^a   Case, Michael ^a   Kollack Walker, Sara ^a   Ascher Svanum, Haya ^a   Ball, Tamara ^b   Kapur, Shitij ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b I3 Statprobe ^*  (United States)

Author keywords

Antipsychotic drugs; Growth mixture modeling; Heterogeneity; Response patterns; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960329069     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.03.015     Document Type: Article

References (28)

1. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 2008, 34(6):1163-1171.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
3. Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., Walker D.J., Roychowdhury S.M., Kane J.M. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am. J. Psychiatry 2005, 162(10):1879-1887.
4. Case M., Stauffer V.L., Ascher-Svanum H., Conley R., Kapur S., Kane J.M., Kollack-Walker S., Jacob J., Kinon B.J. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol. Med 2010, 10.1017/S0033291710001893.
5. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Department of Health, Education, and Welfare, Washington, DC. revised ed.
6. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
7. Kane J.M., Osuntokun O., Kryzhanovskaya L.A., Xu W., Stauffer V.L., Watson S.B., Breier A. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J. Clin. Psychiatry 2009, 70(4):572-581.
8. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
9. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A., Study Group H.G.G.N. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res. 2006, 81(1):1-15.
10. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol. Bull. 1993, 29(2):309-314.
11. Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 2006, 26(2):157-162.
12. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 2006, 26(5):453-461.
13. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008, 102(1-3):230-240.
14. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. 2005, 79(2-3):231-238.
15. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32(9):1903-1910.
16. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol. Psychiatry 2010, 68(1):86-92.
17. Levine S.Z., Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr. Bull. 2010, 36(3):624-632.
18. Levine S.Z., Rabinowitz J., Case M., Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J. Clin. Psychopharmacol. 2010, 30(4):446-449.
19. Levine S.Z., Lurie I., Kohn R., Levav I. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr. Res. 2010, 126(1-3):184-191. (Electronic publication ahead of print 2010 Nov 18).
20. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., Study Group H.G.D.H. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 2003, 160(8):1396-1404.
21. Marques T.R., Arenovich T., Agid O., Sajeev G., Muthén B., Chen L., Kinon B.J., Kapur S. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol. Med 2010, (Electronic publication ahead of print 2010 Oct 20, 1-8). 10.1017/S0033291710002035.
22. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
23. Muthén B., Muthén L. Mplus-Statistical Analysis with Latent Variables-User's Guide 2007, Muthén and Muthén, Los Angeles, CA. Fifth ed.
24. Muthén B., Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 1999, 55(2):463-469.
25. Muthén B., Brown C.H., Masyn K., Jo B., Khoo S.T., Yang C.C., Wang C.P., Kellam S.G., Carlin J.B., Liao J. General growth mixture modeling for randomized preventive interventions. Biostatistics 2002, 3(4):459-475.
26. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
27. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997, 17(5):407-418.
28. World Health Organization Statistics on Schizophrenia 6-9-2010. http://www.who.int/mental_health/management/schizophrenia/en/index.html.